Hair shedding can occur during weight-loss treatment, but a change in hair does not identify its cause on its own. Medication effects, weight changes and other conditions can overlap.

Wegovy’s prescribing information reports hair loss in 3.3% of adults receiving the 2.4-milligram injection in a pooled group of weight-reduction studies, compared with 1% receiving placebo. The label describes these reactions as associated with weight reduction. Those figures apply to the specified studies and dose, not every semaglutide product or formulation.
Shedding and hair loss differ
The American Academy of Dermatology identifies substantial weight loss as one possible trigger for excessive shedding, called telogen effluvium. Shedding can appear months after a physical stressor. Other forms of hair loss have different causes and may need different treatment.
A clinician or dermatologist can assess the pattern, timing, medications and possible nutritional or medical factors. Wegovy’s medication guide advises discussing side effects that are bothersome or do not go away with a healthcare provider.
Trial percentages describe groups of participants. They cannot determine an individual’s diagnosis or guarantee that their hair will recover on a particular schedule.
Updated Oct. 4, 2026: Clarifies dose-specific trial findings and the distinction between shedding and other hair loss.
